0001439222-24-000054.txt : 20240305 0001439222-24-000054.hdr.sgml : 20240305 20240305162043 ACCESSION NUMBER: 0001439222-24-000054 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gheuens Sarah CENTRAL INDEX KEY: 0001881190 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 24720746 MAIL ADDRESS: STREET 1: C/O AGIOS PHARMACEUTICALS, INC. STREET 2: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080703 4 1 wk-form4_1709673617.xml FORM 4 X0508 4 2024-03-01 0 0001439222 AGIOS PHARMACEUTICALS, INC. AGIO 0001881190 Gheuens Sarah 88 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer 1 Common stock 2024-03-01 4 M 0 3834 0 A 37708 D Common stock 2024-03-05 4 S 0 1293 32.57 D 36415 D Common stock 2024-03-01 4 M 0 4000 0 A 40415 D Common stock 2024-03-05 4 S 0 1349 32.57 D 39066 D Restricted stock units 2024-03-01 4 A 0 17000 0 A Common stock 17000 17000 D Stock options (right to buy) 32.27 2024-03-01 4 A 0 60000 0 A 2034-03-01 Common stock 60000 60000 D Restricted stock units 2024-03-01 4 M 0 3834 0 D Common stock 3834 3833 D Restricted stock units 2024-03-01 4 M 0 4000 0 D Common stock 4000 8000 D Includes 2,587 shares purchased through the Company's employee stock purchase plan. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter. The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. /s/ William Cook, as attorney-in-fact for Sarah Gheuens 2024-03-05